Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Richard Greil, Alexander Egle et al.|Blood|2015Cited by 186
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study ResultsHeinz Gisslinger, Christoph Klade, Veronika Buxhofer‐Ausch et al.|Blood|2018Cited by 18
Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera StudVeronika Buxhofer‐Ausch, Richard Greil, Heinz Gisslinger et al.|Blood|2015Cited by 1
Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera PatientHeinz Gisslinger, Richard Greil, Veronika Buxhofer‐Ausch et al.|Blood|2015Cited by 0
Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II StudyHeinz Gisslinger, Richard Greil, Veronika Buxhofer‐Ausch et al.|Blood|2014Cited by 0